Year-end report October – December 2023
Business Highlights during the fourth quarter 2023 · Encouraging preclinical data using uTREAT in non-small cell lung cancer · Announcing the submission of the clinical trial application to the European Medicines Agency for the investigation of uTRACE in a phase 2 trial · Advancing the theranostics by ongoing momentum in development pipeline with data and regulatory progress Copenhagen, Denmark, 22 February 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the the Year-end report October – December 31, 2023. The Year-end report is available as